RESPIRATORY INHALERS MARKET SIZE TO REACH USD 5 BILLION BY 2025, GROWING AT A CAGR OF 9% DURING THE FORECAST PERIOD

Respiratory Inhalers Market Size, Share, Trends, Analysis Report by Product (Metered Dosage and Dry Powder Inhaler), Patient (Adults and Pediatric), Distribution Channels (Hospital Pharmacies, Retail, and Online), and Geography (North America, Europe, APAC, Latin America, and the Middle East & Africa) Industry Analysis Report, Regional Outlook, Growth Trends, Competitive Landscape, & Forecast, 2020-2025

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

219 Pages

icon-table

40 Tables

icon-chart

125 Charts

icon-region

5 Regions

icon-country

18 Countries

icon-company

19 Companies

icon-market

4 Market Segment

GLOBAL RESPIRATORY INHALERS MARKET REPORT SCOPE

Report Attribute Details
MARKET SIZE (REVENUE) USD 5 BILLION (2025)
CAGR 9% (2020-2025)
Base Year 2019
Historic Year 2018
Forecast Year 2020-2025
Market Segments Product (Metered Dosage and Dry Powder Inhaler), Patient (Adults and Pediatric), Distribution Channels (Hospital Pharmacies, Retail, and Online)
Geographic Analysis North America, Europe, APAC, Latin America, and Middle East & Africa
Countries Covered US, Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, Australia, India, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, and Turkey

INDUSTRY INSIGHTS

The global respiratory inhalers market size will reach USD 5 billion by 2025, growing at a CAGR of 9% during the forecast period. The market is one of the steadily growing segments in the global medical devices market. The steady growth can be attributed to the growing prevalence of asthma, COPD, and cystic fibrosis and the outbreak of the COVID-19 pandemic. The prevalence of COPD and other respiratory disorders has increased at a significant rate over the last few years across the globe. According to the WHO, COPD is expected to emerge as the third leading cause of death across the world by 2025. The increasing incidence of respiratory diseases and the growing demand for treatment options for respiratory disorders are fueling the market growth of therapeutic respiratory care devices. Further, the presence of established infrastructure in several countries of North America, Europe, and APAC, coupled with the availability of well-developed technologies that allow early implementation of advanced inhalation technologies, increases the demand for inhalers. Favorable government initiatives in emerging economies toward improvising standard healthcare infrastructure and increased focus on healthcare expenditure are also aiding to focus on offering high-quality healthcare services.

SNIPPETS

  • The metered dosage inhalers segment is likely to register an incremental growth of over $1 billion by 2025 as MDIs combine the practical benefits of size, portability, convenience, and unobtrusiveness.
  • The adult segment is expected to grow at the highest CAGR of over 10% during the period 2019–2025. The growth is on account of the high prevalence of COPD and other respiratory disorders.
  • The online segment is observed to register growth at the highest CAGR of over 10% from 2019–2025. The growth is because of the increasing popularity of e-commerce channels in the healthcare sector.
  • The APAC region is expected to touch revenue of close to $1.4 billion by 2025. The growth in the region is driven mainly by increased affordability and the presence of a large patient population.
  • The respiratory inhalers market in India is expected to grow significantly due to the presence of high asthma and COPD population.

GLOBAL RESPIRATORY INHALERS MARKET SEGMENTATION

This research report includes a detailed segmentation by

  • Products
  • Patient
  • Distribution Channel
  • Geography

INSIGHTS BY PRODUCT

 The metered dosage inhalers segment is expected to over 2.5 billion by 2025 due to the outbreak of COVID-19, which has led to the increased usage of inhalers among the patients. Pressurized metered dosage inhalers (pMDIs) and dry-powder inhalers (DPIs) are commonly used among end-users. pMDIs are mostly used among developing and underdeveloped countries due to their low price and easy availability in pharmacies. DPI, breath-actuated inhalers, and soft mist inhalers will gain popularity in developed countries such as the US, the UK, and Germany as the treatment in the countries are covered under insurance and reimbursement policies. Developed countries are the matured market, where most advanced versions of smart inhalers are used among people. MDIs are considered as the first line of treatment for major respiratory disorders such as COPD and Asthma. However, a major challenge faced by the segment is the lack of awareness among patients and healthcare providers regarding the correct usage of MDIs.

In 2019, the DPI segment accounted for the share of 46% of the global respiratory inhalers market. The increased efficiency of drug usage is the major driving force for the growth of DPIs. Drug deposition in the lung was twice that of pMDI, which suggests a low dosage of the drug with reduced side-effects helps to achieve the same degree of asthma control. The majority of DPIs have the dose counter, which allows detecting the number of dosages remaining. These devices are user-friendly and convenient; hence they are preferred by patients over MDIs.

INSIGHTS BY PATIENT 

The respiratory inhalers market is segmented into pediatric and adults age groups. In. 2019, the adult segment accounted for the share of 68%, and the pediatric population constituted a share of 32% in the respiratory inhalers market. The adult population is widely exposed to several environmental risk factors such as air and workplace pollutions and the consumption of tobacco. This contributes to the high share of the adult population in the market. While the prevalence of asthma is increasing in several countries, multiple factors are affecting the incidence of asthma in the adult population. With the eruption of the COVID-19 pandemic, the number of adults infected is higher than pediatric and neonates populations. Therefore, the demand for inhalers has gone drastically up across the globe due to the spread of the virus.

Managing asthma in pediatrics is not as adults. Pediatric patients are overly sensitive and require a high level of care and comfort and convenient device usage. MDIs, along with spacers, are widely used to treat children suffering from respiratory disorders. Corticosteroids and bronchodilator therapies are routinely delivered by pMDI and the spacer system for children under the age of five years. The prevalence of asthma is higher in urban areas than in rural areas. The incidence of asthma is higher in high-income countries than low- and middle-income ones.

INSIGHTS BY DISTRIBUTION CHANNEL

The hospital pharmacy segment accounted for a share of 47%. Hospitals are the first point of contact for the evaluation and treatment of respiratory diseases such as asthma and COPD. As the number of hospitals has grown over the period, the count of hospital pharmacies has also increased. In the middle- and low-income countries, several smaller clinics, nursing homes have tie-ups with hospital pharmacies to refer patients to purchase branded medical devices for usage.

In 2019, the retail distribution channel segment constituted a share of 43% of the global respiratory inhalers market. Retail pharmacies are picking up pace in the healthcare industry and developing countries such as India, China, Mexico, and other countries. Retail stores have been a proven model for consumers to buy products and services. The retail market holds immense potential because most countries are underpenetrated. In developing countries, the demand for retail pharmacy stores is increasing drastically. Major retail pharmacies in India include Noble plus pharmacy, Apollo pharmacy, Wellness forever pharmacy, Med plus health services, and other pharmacies. Hence, with the increase in the global disease burden in the population, the retail pharmacy sector is expected to observe surge. Although the online segment is expected to increase its reach during the forecast period, the segment constituted only a 10% market share in 2019. 

INSIGHTS BY GEOGRAPHY

North America has dominated the global inhalers market, and dominance is mainly due to the increase in the prevalence of several respiratory diseases. The US has been the earliest adopters of the latest inhaler technology to reduce the rate of COPD. In North America, both the US and Canada experienced a large-scale adoption of these devices over the last decade. The rise in pollution rates, along with the growing number of cases of respiratory troubles, is one of the major reasons that boosts the overall demand in the region.  Besides, since the outbreak of the COVID pandemic, the need for inhalers has grown significantly in ICUs and emergency rooms. A large population on a medical ventilator are supported with inhalers for increased effectiveness of the medicine. Although the market is expected to grow at a slower rate than other regions, there is a surge in demand for inhalers in the region, especially in the US owing to the COVID-19 pandemic. The country will witness growth as the national health spending is projected to grow at an average annual rate of over 5% during the period 2019–2028, reaching $6.2 trillion by 2028.

INSIGHTS BY VENDORS

The global respiratory inhalers market share is fragmented with the presence of several global, regional, and local vendors offering a wide range of products. GSK, Novartis, BOEHRINGER INGELHEIM, Cipla, and AstraZeneca are the key players dominating the global market. Although large vendors dominate the market, they are witnessing heavy competition from regional and local companies from India, China, Italy, and Germany. Many regional vendors are also offering cost-effective products in Europe, APAC, and the Middle East & Africa regions.

The global respiratory inhalers market research report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:

By Product

  • Metered Dosage Inhaler
  • Dry Powder Inhaler

By Patient

  • Adults
  • Pediatric

By Distribution Channel

  • Hospital Pharmacies
  • Retail
  • Online

By Geography

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • APAC
    • China
    • Japan
    • South Korea
    • Australia
    • India
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Turkey

Frequently Asked Questions

What are the respiratory inhalers market size and growth rate during the forecast period?

Respiratory inhalers market size is expected reach revenues of over $5 billion by 2025, growing at a CAGR of over 9%.

What are the factors impacting the growth of the respiratory inhalers market share?

The growing prevalence of asthma, COPD, and cystic fibrosis and the outbreak of the COVID-19 pandemic are the major factors impacting the growth of the global respiratory inhalers market.

How is the growth of the hospital pharmacies segment influencing the respiratory inhalers market growth?

Hospitals are the first point of contact for the evaluation and treatment of respiratory diseases such as asthma and COPD. Also, the hospital pharmacy segment accounted for a share of 47% of the global respiratory inhalers market

Who are the leading vendors in the respiratory inhalers market, and what are their market shares?

The leading vendors in the global respiratory inhalers market are GlaxoSmithKline, Novartis, Boehringer Ingelheim, Cipla, AstraZeneca

Which distribution channel will witness the highest growth in selling the respiratory inhalers?

The online segment is observed to register growth at the highest CAGR of over 10% from 2019–2025. The growth is because of the increasing popularity of e-commerce channels in the healthcare sector.

Download Free Sample

The respiratory inhalers market by revenue is expected to grow at a CAGR of over 9% during the period 2019–2025.

The following factors are likely to contribute to the growth of the respiratory inhalers market during the forecast period:

  • Increase in Usage of Smart Inhaler
  • Introduction of Soft Mist Inhalers
  • Increase in Target Population
  • Surge in Inhalers Usage due to COVID-19

Base Year:                  2019

Forecast Year:           2020–2025

The study considers the present scenario of the respiratory inhalers market and its market dynamics for the period 2019−2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspect of the market. It profiles and examines leading companies and other prominent ones operating in the market.

Prominent Vendors

  • GlaxoSmithKline
    • Business Overview
    • Product Offerings
    • Key Strengths
    • Key Strategies
    • Key Opportunities
  • Novartis
  • Boehringer Ingelheim
  • Cipla
  • AstraZeneca

Other Prominent Vendors 

  • Propeller Health
    • Business Overview
    • Product Offerings
  • Beximco Pharmaceuticals (Beximco Pharma)
  • H&T Presspart
  • Cohero Health
  • CHIESI Farmaceutici
  • Mundipharma
  • 3M
  • HELTMAN Medikal
  • Adherium
  • Luckys Pharma
  • Amiko Digital Health
  • Teva Pharmaceutical Industries
  • Findair Sp.z.o.o
  • Vectura Group

Segmentation by Products 

  • Metered Dosage Inhaler
  • Dry Powder Inhaler

Segmentation by Patient

  • Adults
  • Pediatric

Segmentation by Distribution Channel

  • Hospital Pharmacies
  • Retail
  • Online

Segmentation by Geography

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • APAC
    • China
    • Japan
    • South Korea
    • Australia
    • India
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Turkey

1 Research Methodology

2 Research Objectives

3 Research Process

4 Scope & Coverage

4.1 Market Definition

4.1.1 Inclusions

4.1.2 Exclusions

4.2 Base Year

4.3 Scope of The Study

4.3.1 Market Segmentation by Product

4.3.2 Market Segmentation by Patient

4.3.3 Market Segmentation by Distribution Channel

4.3.4 Market Segmentation by Geography

5 Report Assumptions & Caveats

5.1 Key Caveats

5.2 Currency Conversion

5.3 Market Derivation

6 Market at a Glance

7 Introduction

7.1 Overview

7.2 Impact Of Covid-19

7.2.1 Overview

8 Market Opportunities & Trends

8.1 Increase In Usage Of Smart Inhaler

8.2 Introduction Of Soft Mist Inhalers

8.3 Surge In Inhalers Usage Due To Covid-19

9 Market Growth Enablers

9.1 Respiratory Inhalers Designed To The Specific Drugs

9.2 Technological Advances In Inhalers

9.3 Increase In Target Population

10 Market Restraints

10.1 Lack Of Awareness And Errors In Usage Of Inhalers

10.2 Challenges In Inhalers Usage

10.3 Global Warming Impacting The Use Of Inhalers

11 Market Landscape

11.1 Market Overview

11.2 Market Size & Forecast

11.3 Five Forces Analysis

11.3.1 Threat Of New Entrants

11.3.2 Bargaining Power Of Buyers

11.3.3 Bargaining Power Of Suppliers

11.3.4 Threat Of Substitutes

11.3.5 Competitive Rivalry

12 Respiratory Inhalers Market by Product

12.1 Snapshot & Growth Engine

12.2 Overview

12.3 Metered Dosage Inhalers

12.3.1 Overview

12.3.2 Size & Forecast

12.3.3 Snapshot & Growth Engine

12.3.4 Pressurized Metered Dosage Inhalers

12.3.5 Overview

12.3.6 Size & Forecast

12.3.7 Breath Actuated Mdis

12.3.8 Overview

12.3.9 Size & Forecast

12.4 Dry Powder Inhalers

12.4.1 Overview

12.4.2 Size & Forecast

12.5 Soft Mist Inhalers

12.5.1 Overview

12.5.2 Size & Forecast

13 Respiratory Inhalers Market by Patient Group

13.1 Market Snapshot & Growth Engine

13.2 Overview

13.3 Pediatric Patients

13.3.1 Overview

13.3.2 Size & Forecast

13.4 Adults

13.4.1 Overview

13.4.2 Size & Forecast

14 Respiratory Inhalers Market by Distribution Channel

14.1 Snapshot & Growth Engine

14.2 Overview

14.3 Hospital Pharmacies

14.3.1 Overview

14.3.2 Size & Forecast

14.4 Retail Pharmacies

14.4.1 Overview

14.4.2 Size & Forecast

14.5 Online

14.5.1 Overview

14.5.2 Size & Forecast

15 Respiratory Inhalers Market by Geography

15.1 Snapshot & Growth Engine

15.2 Geographic Overview

16 North America

16.1 Overview

16.2 Size & Forecast

16.3 Key Countries

16.3.1 US: Respiratory Inhalers Market Size & Forecast

16.3.2 Canada: Size & Forecast

17 Europe

17.1 Overview

17.2 Size & Forecast

17.3 Key Countries

17.3.1 UK: Respiratory Inhalers Market Size & Forecast

17.3.2 Germany: Size & Forecast

17.3.3 France: Respiratory Inhalers Market Size & Forecast

17.3.4 Spain: Size & Forecast

17.3.5 Italy: Respiratory Inhalers Market Size & Forecast

18 APAC

18.1 Overview

18.2 Size & Forecast

18.3 Key Countries

18.3.1 China: Respiratory Inhalers Market Size & Forecast

18.3.2 Japan: Size & Forecast

18.3.3 India: Respiratory Inhalers Market Size & Forecast

18.3.4 South Korea: Market Size & Forecast

18.3.5 Australia: Respiratory Inhalers Market Size & Forecast

19 Latin America

19.1 Overview

19.2 Size & Forecast

19.3 Key Countries

19.3.1 Brazil: Respiratory Inhalers Market Size & Forecast

19.3.2 Mexico: Size & Forecast

19.3.3 Argentina: Respiratory Inhalers Market Size & Forecast

20 Middle East & Africa

20.1 Overview

20.2 Size & Forecast

20.3 Key Countries

20.3.1 Turkey: Respiratory Inhalers Market Size & Forecast

20.3.2 South Africa: Size & Forecast

20.3.3 Saudi Arabia: Respiratory Inhalers Market Size & Forecast

21 Competitive Landscape

21.1 Competition Overview

21.2 Market Share Analysis

21.2.1 Cipla

21.2.2 GSK

21.2.3 Novartis

21.2.4 Boehringer Ingelheim

21.2.5 Astrazeneca

22 Key Company Profiles

22.1 Glaxosmithkline

22.1.1 Business Overview

22.1.2 Product Offerings

22.1.3 Key Strategies

22.1.4 Key Strengths

22.1.5 Key Opportunities

22.2 Novartis

22.2.1 Business Overview

22.2.2 Product Offerings

22.2.3 Key Strategies

22.2.4 Key Strengths

22.2.5 Key Opportunities

22.3 Boehringer Ingelheim

22.3.1 Business Overview

22.3.2 Product Offerings

22.3.3 Key Strategies

22.3.4 Key Strengths

22.3.5 Key Opportunities

22.4 Cipla

22.4.1 Business Overview

22.4.2 Product Offerings

22.4.3 Key Strategies

22.4.4 Key Strengths

22.4.5 Key Opportunities

22.5 AstraZeneca

22.5.1 Business Overview

22.5.2 Product Offerings

22.5.3 Key Strategies

22.5.4 Key Strengths

22.5.5 Key Opportunities

23 Other Prominent Vendors

23.1 Propeller Health

23.1.1 Business Overview

23.1.2 Product Offerings

23.2 Beximco Pharmaceuticals

23.2.1 Business Overview

23.2.2 Product Offerings

23.3 H&T Presspart

23.3.1 Business Overview

23.3.2 Product Offerings

23.4 Cohero Health

23.4.1 Business Overview

23.4.2 Product Offerings

23.5 CHIESI Farmaceutici

23.5.1 Business Overview

23.5.2 Product Offerings

23.6 Mundipharma

23.6.1 Business Overview

23.6.2 Product Offerings

23.7 3M

23.7.1 Business Overview

23.7.2 Product Offerings

23.8 HELTMAN Medikal

23.8.1 Business Overview

23.8.2 Product Offerings

23.9 Adherium

23.9.1 Business Overview

23.9.2 Product Offerings

23.10 Luckys Pharma

23.10.1 Business Overview

23.10.2 Product Offerings

23.11 Amiko Digital Health

23.11.1 Business Overview

23.11.2 Product Offerings

23.12 Teva Pharmaceutical Industries

23.12.1 Business Overview

23.12.2 Product Offerings

23.13 Findair Sp. z o. o.

23.13.1 Business Overview

23.13.2 Product Offerings

23.14 Vectura Group

23.14.1 Business Overview

23.14.2 Product Offerings

24 Report Summary

24.1 Key Takeaways

24.2 Strategic Recommendations

25 Quantitative Summary

25.1 By Geography

25.2 By Patients

25.3 By Product

25.4 By Distribution Channel

26 Appendix

26.1 Abbreviations

List Of Exhibits 

Exhibit 1               Market Segmentation of Global Respiratory Inhalers Market

Exhibit 2               Market Size Calculation Approach 2019

Exhibit 3               Evolution of Respiratory Inhalers

Exhibit 4               Respiratory Inhalers Family Tree

Exhibit 5               Decision Tree For COVID-19 Patients

Exhibit 6               Mortality Rate of COVID-19 by Age Group

Exhibit 7               Impact of Increase in Usage of Smart Inhaler

Exhibit 8               Impact of Introduction of Soft Mist Inhalers

Exhibit 9               Comparison of Drug Delivery Efficiency in pMDI & SMI - Fractionation of Dosage From pMDI & SMIs

Exhibit 10             Impact of Surge in Inhalers Usage due to COVID-19

Exhibit 11             COVID-19 Cases Comparison – Regional wise by WHO

Exhibit 12             Impact of Respiratory Inhalers Designed to the Specific Drugs

Exhibit 13             Impact of Technological Advances in Inhalers

Exhibit 14             Impact of Increase in Target Population

Exhibit 15             Population Aged 60 Years & Above: Segmented by Region 2017 & 2050

Exhibit 16             Prevalence of COPD in Various Countries

Exhibit 17             Impact of Lack of Awareness and Errors in Usage of Inhalers

Exhibit 18             Common Errors in pMDI Usage from Multiple Studies

Exhibit 19             Common Errors in DPI Usage from Multiple Studies

Exhibit 20             Critical Errors During the Usage of MDI

Exhibit 21             Critical Errors Occur During the Usage of DPI

Exhibit 22             Impact of Challenges in Inhaler Usage

Exhibit 23             Factors Impacting Patient Onboarding & Adherence

Exhibit 24             Impact of Global Warming Impacting the Inhaler Usage

Exhibit 25             Global Respiratory Inhalers Market 2019–2025 ($ million)

Exhibit 26             Global Respiratory Inhalers Market by Product: 2019 & 2025 Percentage Share Comparison

Exhibit 27             Global Respiratory Inhalers Market by Patient: 2019 & 2025 (% share comparison)

Exhibit 28             Global Respiratory Inhalers Market by Distribution Channel: 2019 & 2025 (% share comparison)

Exhibit 29             Global Respiratory Inhalers Market by Geography: 2019 & 2025 (% share comparison)

Exhibit 30             Five Forces Analysis 2019

Exhibit 31             Incremental Growth by Product 2019 & 2025

Exhibit 32             Global Respiratory Inhalers Market by Product

Exhibit 33             Global Market by Product: Incremental Growth

Exhibit 34             Global Market by Product: Absolute Growth

Exhibit 35             COVID-19 Impact on Product Segment

Exhibit 36             Respiratory Inhalers Market Product – Metered Dosage Inhaler: Incremental Growth & Absolute Growth Comparison

Exhibit 37             Global Metered Dosage Inhaler Market 2019–2025 ($ million)

Exhibit 38             Incremental Growth by Segment 2019 & 2025

Exhibit 39             Global Pressurized Metered Dosage Market: Incremental Growth & Absolute Growth Comparison

Exhibit 40             Global Pressurized Metered Dosage Market 2019–2025 ($ million)

Exhibit 41             Global Breath Actuated MDIs Market: Incremental Growth & Absolute Growth Comparison

Exhibit 42             Global Breath Actuated Metered Dosage Inhalers Market 2019–2025 ($ million)

Exhibit 43             Global Dry Powder Market: Incremental Growth & Absolute Growth Comparison

Exhibit 44             Global Dry Powdered Market 2019–2025 ($ million)

Exhibit 45             Global SMI Market: Incremental Growth & Absolute Growth Comparison

Exhibit 46             Global Soft Mist Inhaler Market 2019–2025 ($ million)

Exhibit 47             Incremental Growth by Patient Group 2019 & 2025

Exhibit 48             Global Respiratory Inhalers Market by Patient Group

Exhibit 49             Global Market by Patient Group: Incremental Growth

Exhibit 50             Global Market by Patient Group: Absolute Growth

Exhibit 51             Global Market by Patient Group: COVID-19 Impact

Exhibit 52             Socio-Economic Cost of Childhood Asthma

Exhibit 53             Global Market by Pediatric Patient Group: Incremental Growth & Absolute Growth Comparison

Exhibit 54             Global Market by Pediatric Patients 2019–2025 ($ million)

Exhibit 55             Global Market by Adults Patient Group: Incremental Growth & Absolute Growth Comparison

Exhibit 56             Global Market by Adult Patient Group 2019–2025 ($ million)

Exhibit 57             Incremental Growth by Segment 2019 & 2025

Exhibit 58             Respiratory Inhalers Classification Based on Distribution Channel

Exhibit 59             Global Respiratory Inhalers Market by Product: Incremental Growth

Exhibit 60             Global Market by Product: Absolute Growth

Exhibit 61             COVID-19 Impact on Product Segment

Exhibit 62             Respiratory Inhalers Market Distribution Channel – Hospital Pharmacy: Incremental Growth & Absolute Growth Comparison

Exhibit 63             Global by Hospital Pharmacies 2019–2025 ($ million)

Exhibit 64             Respiratory Inhalers Market Distribution Channel – Retail Pharmacy: Incremental Growth & Absolute Growth Comparison

Exhibit 65             Global Market by Retail Pharmacies 2019–2025 ($ million)

Exhibit 66             Market Distribution Channel – Online: Incremental Growth & Absolute Growth Comparison

Exhibit 67             Global Market by Online Distribution Channel 2019–2025 ($ million)

Exhibit 68             Incremental Growth by Geography 2019 & 2025

Exhibit 69             Global Respiratory Inhalers Market by Geography

Exhibit 70             Global Market by Geography: Key Countries 2019 ($ million)

Exhibit 71             Global Market by Geography: Incremental Growth

Exhibit 72             Global Market by Geography: Absolute Growth

Exhibit 73             COVID-19 Impact on Geography Segment

Exhibit 74             Respiratory Inhalers Market in North America: Key Countries ($ million)

Exhibit 75             Market in North America: Incremental Growth & Absolute Growth Comparison

Exhibit 76             Market in North America 2019–2025 ($ million)

Exhibit 77             Incremental Growth in North America 2019 & 2025

Exhibit 78             Asthma Prevalence in US 2018

Exhibit 79             Market in US 2019–2025 ($ million)

Exhibit 80             Market in Canada 2019–2025 ($ million)

Exhibit 81             Hospitalization Rate of Asthma Patients in European Countries

Exhibit 82             Respiratory Inhalers Market in Europe: Key Countries ($ million)

Exhibit 83             Market in Europe: Incremental Growth & Absolute Growth Comparison

Exhibit 84             Market in Europe 2019–2025 ($ million)

Exhibit 85             Incremental Growth in North America 2019 & 2025

Exhibit 86             Market in UK 2019–2025 ($ million)

Exhibit 87             Market in Germany 2019–2025 ($ million)

Exhibit 88             Market in France 2019–2025 ($ million)

Exhibit 89             Market in Spain 2019–2025 ($ million)

Exhibit 90             Global Market in Italy 2019–2025 ($ million)

Exhibit 91             Respiratory Inhalers Market in APAC: Key Countries ($ million)

Exhibit 92             Market in APAC: Incremental Growth & Absolute Growth Comparison

Exhibit 93             Market in APAC 2019–2025 ($ million)

Exhibit 94             Incremental Growth in APAC 2019 & 2025

Exhibit 95             Market in China 2019–2025 ($ million)

Exhibit 96             Market in Japan 2019–2025 ($ million)

Exhibit 97             Market in India 2019–2025 ($ million)

Exhibit 98             Market in South Korea 2019–2025 ($ million)

Exhibit 99             Market in Australia 2019–2025 ($ million)

Exhibit 100          Respiratory Inhalers Market in Latin America: Key Countries ($ million)

Exhibit 101          Market in Latin America: Incremental Growth & Absolute Growth Comparison

Exhibit 102          Market in Latin America 2019–2025 ($ million)

Exhibit 103          Incremental Growth in Latin America 2019 & 2025

Exhibit 104          Market in Brazil 2019–2025 ($ million)

Exhibit 105          Market in Mexico 2019–2025 ($ million)

Exhibit 106          Market in Argentina 2019–2025 ($ million)

Exhibit 107          Respiratory Inhalers Market in Middle East & Africa: Key Countries ($ million)

Exhibit 108          Market in Middle East & Africa: Incremental Growth & Absolute Growth Comparison

Exhibit 109          Market in Middle East & Africa 2019–2025 ($ million)

Exhibit 110          Incremental Growth in Middle East & Africa 2019 & 2025

Exhibit 111          Market in Turkey 2019–2025 ($ million)

Exhibit 112          Market in South Africa 2019–2025 ($ million)

Exhibit 113          Market in Saudi Arabia 2019–2025 ($ million)

Exhibit 114          GlaxoSmithKline Revenue 2017-2019 ($ million)

Exhibit 115          GlaxoSmithKline: Research & Development Expenditure ($ million)

Exhibit 116          Novartis Revenue 2017-2019 ($ million)

Exhibit 117          Novartis: Research & Development Expenditure ($ million)

Exhibit 118          Boehringer Ingelheim Revenue 2018 & 2019 ($ billion)

Exhibit 119          Boehringer Ingelheim: Research & Development Expenditure ($ million)

Exhibit 120          Boehringer Ingelheim Revenue by Business Segments 2019

Exhibit 121          Cipla Revenue 2017-2019 ($ billion)

Exhibit 122          Cipla: Percentage Share of R&D Expenditure in Revenue

Exhibit 123          AstraZeneca Revenue 2017-2019 ($ million)

Exhibit 124          AstraZeneca: Research & Development Expenditure ($ million)

Exhibit 125          AstraZeneca Revenue by Segments ($ million)

               

List Of Tables    

Table 1                 Key Caveats

Table 2                 Currency Conversion 2013−2019

Table 3                 Smart Inhalers Offered in the Market

Table 4                 Prescribed Drugs with Inhalers Devices

Table 5                Commonly Used DPIs Produced by Key Players

Table 6                Limitations Associated with Various Respiratory Inhalers

Table 7                Advantages and Disadvantages of Metered Dosage Inhaler

Table 8                Advantages and Disadvantages of Dry Powder Inhalers

Table 9                Advantages and Disadvantages of SMIs

Table 10               Guidelines – Choice of Inhalers for Children Younger than five years

Table 11               Overview of Distribution Channels in Key Markets

Table 12               Comparison of Online vs. Conventional Pharmacy

Table 13               Global Respiratory Inhalers Market: Vendors Ranking

Table 14               GlaxoSmithKline: Major Product Offerings

Table 15               Novartis: Major Product Offerings

Table 16               Boehringer Ingelheim: Major Product Offerings

Table 17               Cipla: Major Product Offerings

Table 18               AstraZeneca: Major Product Offerings

Table 19               Propeller Health: Major Product Offerings

Table 20               Beximo Pharmaceuticals: Major Product Offerings

Table 21               H&T Presspart: Major Product Offerings

Table 22               Cohero Health: Major Product Offerings

Table 23               CHIESI Farmaceutici: Major Product Offerings

Table 24               Mundipharma: Major Product Offerings

Table 25               3M: Major Product Offerings

Table 26               HELTMAN Medikal: Major Product Offerings

Table 27               Adherium: Major Product Offerings

Table 28               Luckys Pharma: Major Product Offerings

Table 29               Amiko Digital Health: Major Product Offerings

Table 30               Teva Pharmaceutical Industries: Major Product Offerings

Table 31               Findair Sp.z.o.o.: Major Product Offerings

Table 32               Vectura Group: Major Product Offerings

Table 33               Global Respiratory Inhalers Market by Geography 2019−2025 ($ million)

Table 34               Global Market by Geography 2019−2025 (%)

Table 35               Global Respiratory Inhalers Market by Patients 2019−2025 ($ million)

Table 36               Global Market by Patients 2019−2025 (%)

Table 37               Global Respiratory Inhalers Market by Product 2019−2025 ($ million)

Table 38               Global Market by Product 2019−2025 (%)

Table 39               Global Respiratory Inhalers Market by Distribution Channel 2019−2025 ($ million)

Table 40               Global Market by Distribution Channel 2019−2025 (%)

Select a license type that suits your business needs

single-user Single User Licence
$3500.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$4000.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$5000.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Licence Types What are these?

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date